PainReform Ltd. shared business updates for the first half of 2025, focusing on pharmaceutical advancements and energy analytics progress. The company invested in LayerBio for a cataract therapy targeting a $9B market and advanced PRF-110. DeepSolar achievements included an energy management app, NVIDIA partnership, and a pilot project with Econergy.

In the pharmaceutical sector, PainReform acquired a majority interest in LayerBio, introducing OcuRing™-K for pain control post-cataract surgery. PRF-110 showed efficacy post-bunionectomy, despite Phase 3 trial results. Meanwhile, DeepSolar expanded its Smart Energy Management solutions with AI analytics and entered into a commercial agreement following a successful pilot project.

Financially, research and development costs decreased significantly, general and administrative expenses rose slightly, and the net loss reduced to $2.3M in 2025. PainReform maintained a cash balance of $3.5M and positive working capital of $1.5M. The company is strategically balancing innovation with financial prudence to drive sustainable value across its healthcare and clean energy businesses.

Read more at GlobeNewswire: PainReform Provides Business Update for the Six Months